V
XFOR icon

Veritable’s X4 Pharmaceuticals XFOR Stock Holding History

Veritable’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-421
Closed -$24.5K – 846
2023
Q2 		$24.5K Hold
421
– – ﹤0.01% 884
2023
Q1 		$11K Hold
421
– – ﹤0.01% 891
2022
Q4 		$12.5K Hold
421
– – ﹤0.01% 862
2022
Q3 		$22K Hold
421
– – ﹤0.01% 788
2022
Q2 		$12K Buy
+421
New +$16K ﹤0.01% 900

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Veritable's XFOR Position: Q3 2023 in Review

Veritable sold out of X4 Pharmaceuticals (XFOR) in Q3 2023, closing a stake of 421 shares — an estimated $24.5K sold.

Veritable first reported a position in XFOR in Q2 2022 and held it in 5 quarters. The position peaked at $24.5K in Q2 2023. 91 funds tracked by Wall St. Rank hold XFOR as of Q3 2023.

  • Veritable reported no remaining X4 Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Veritable sold 421 X4 Pharmaceuticals shares in Q3 2023, an estimated $24.5K.
  • Veritable first reported a position in X4 Pharmaceuticals in Q2 2022 and held it in 5 quarters.
  • Veritable's X4 Pharmaceuticals position peaked at $24.5K in Q2 2023.
  • 91 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2023.

Based on Veritable's 13F filing for Q3 2023.